Eprodisate slows the progression of renal disease in patients with AA amyloidosis

Nature Clinical Practice Nephrology

Volumn 3, Issue 11, 2007, Pages 592-593

  Rule, Andrew D ^a   Leung, Nelson ^a  

^a MAYO CLINIC   (United States)

Author keywords

AA amyloidosis; Eprodisate; Renal disease

Indexed keywords

AMYLOID A PROTEIN; ANTIINFECTIVE AGENT; CREATININE; EPRODISATE; PLACEBO; PROTEIN; UNCLASSIFIED DRUG;

AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NEPHROTIC SYNDROME; NOTE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; STRATIFICATION; TREATMENT OUTCOME; URINALYSIS;

EID: 35548957417     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0615     Document Type: Note

References (5)

1. Lachmann HJ et al. (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356: 2361-2371
2. Gillmore JD et al. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358: 24-29
3. th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79: 319-328
4. Zemer D et al. (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314: 1001-1005
5. Tan AU Jr et al. (1995) Renal amyloidosis in a drug abuser. J Am Soc Nephrol 5: 1653-1658